Details for Patent: 10,398,708
Which drugs does patent 10,398,708 protect, and when does it expire?
Patent 10,398,708 protects IMVEXXY and is included in one NDA.
This patent has one hundred and sixty-seven patent family members in twenty-one countries.
Summary for Patent: 10,398,708
| Title: | Vaginal inserted estradiol pharmaceutical compositions and methods |
| Abstract: | In one aspect, compositions and methods for the treatment of vulvovaginal atrophy (VVA) are provided. In one embodiment, the method comprises administering an estrogen to a subject having VVA by inserting a dosage form comprising a liquid pharmaceutical composition. |
| Inventor(s): | Sebastian Mirkin, Julia M. Amadio, Brian A. Bernick |
| Assignee: | TherapeuticsMD Inc |
| Application Number: | US15/893,542 |
| Patent Litigation and PTAB cases: | See patent lawsuits and PTAB cases for patent 10,398,708 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Dosage form; |
Drugs Protected by US Patent 10,398,708
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | AB | RX | Yes | Yes | 10,398,708 | ⤷ Start Trial | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY | ⤷ Start Trial | |||
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-001 | May 29, 2018 | AB | RX | Yes | Yes | 10,398,708 | ⤷ Start Trial | TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA | ⤷ Start Trial | |||
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-002 | May 29, 2018 | AB | RX | Yes | Yes | 10,398,708 | ⤷ Start Trial | TREATMENT OF A SYMPTOM OF VULVAR AND VAGINAL ATROPHY | ⤷ Start Trial | |||
| Mayne Pharma | IMVEXXY | estradiol | INSERT;VAGINAL | 208564-002 | May 29, 2018 | AB | RX | Yes | Yes | 10,398,708 | ⤷ Start Trial | TREATMENT OF MODERATE TO SEVERE DYSPAREUNIA | ⤷ Start Trial | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,398,708
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| European Patent Office | 2782584 | ⤷ Start Trial | 301153 | Netherlands | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 2021C/558 | Belgium | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | 122021000080 | Germany | ⤷ Start Trial |
| European Patent Office | 2782584 | ⤷ Start Trial | LUC00245 | Luxembourg | ⤷ Start Trial |
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
